Cargando…

Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib

BACKGROUND/PURPOSE: Lenvatinib is a first-line treatment for unresectable hepatocellular carcinoma (uHCC). We assessed the value of early alpha-fetoprotein (AFP) response for predicting clinical outcomes with lenvatinib treatment in patients with HBV-related uHCC and elevated AFP levels. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Bo, Shang, Xiao, Shi, Jin-Yu, Cui, Guo-Zhen, Li, Xi, Wang, Nan-Ya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893311/ https://www.ncbi.nlm.nih.gov/pubmed/35251977 http://dx.doi.org/10.3389/fonc.2022.807189

Ejemplares similares

Metabolomic Profiles for HBV Related Hepatocellular Carcinoma Including Alpha-Fetoproteins Positive and Negative Subtypes
por: Sun, Jianping, et al.
Publicado: (2019)

Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China
por: Hou, Gang, et al.
Publicado: (2023)

Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report
por: Qin, Lanqun, et al.
Publicado: (2021)

Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy
por: Qian, Xiangjun, et al.
Publicado: (2020)

Evaluation of the Alpha-Fetoprotein Model for Predicting Recurrence and Survival in Patients With Hepatitis B Virus (HBV)–Related Cirrhosis Who Received Liver Transplantation for Hepatocellular Carcinoma
por: Ren, Ao, et al.
Publicado: (2020)

Hepatocellular carcinoma in children and young patients with chronic HBV infection and the usefulness of alpha‐fetoprotein assessment
por: Tajiri, Hitoshi, et al.
Publicado: (2016)

Racial disparities in alpha‐fetoprotein testing and alpha‐fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients
por: Wu, Guoyi, et al.
Publicado: (2019)

Pre- to postoperative alpha-fetoprotein ratio-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma
por: Yang, Chengkai, et al.
Publicado: (2023)

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
por: Wang, Xiaoping, et al.
Publicado: (2018)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
por: Qin, He-nan, et al.
Publicado: (2022)

Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis
por: Dong, Dong, et al.
Publicado: (2022)

Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection
por: Lin, Kongying, et al.
Publicado: (2021)

Analysis of Serum Paraoxonase 1 Using Mass Spectrometry and Lectin Immunoassay in Patients With Alpha-Fetoprotein Negative Hepatocellular Carcinoma
por: Cao, Xinyi, et al.
Publicado: (2021)

Alpha-Fetoprotein Binding Mucin and Scavenger Receptors: An Available Bio-Target for Treating Cancer
por: Lin, Bo, et al.
Publicado: (2021)

Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy
por: Sun, Li-Yue, et al.
Publicado: (2022)

Inflammatory cytokines and alpha-fetoprotein concentrations for predicting survival in patients with hepatocellular carcinoma
por: Han, Xue, et al.
Publicado: (2019)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Huang, Xiaozhun, et al.
Publicado: (2021)

Beyond liver cancer, more application scenarios for alpha-fetoprotein in clinical practice
por: Ma, Chenyu, et al.
Publicado: (2023)

Serum alpha-fetoprotein as a predictive biomarker for tissue alpha-fetoprotein status and prognosis in patients with hepatocellular carcinoma
por: Wei, Zhewen, et al.
Publicado: (2022)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

HBV-associated intrahepatic cholangiocarcinoma with high serum alpha-fetoprotein: a case report with review of literature
por: Wang, Caixia, et al.
Publicado: (2016)

Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?
por: Lee, Chao-Wei, et al.
Publicado: (2019)

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma
por: Hanif, Hira, et al.
Publicado: (2022)

The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?
por: Hu, Xin, et al.
Publicado: (2022)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Quantitative mass spectrometric analysis of hepatocellular carcinoma biomarker alpha-fetoprotein
por: Chen, Chen-Chun, et al.
Publicado: (2023)

Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization
por: He, Chao, et al.
Publicado: (2017)

Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma
por: Welberry, Christopher, et al.
Publicado: (2020)

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
por: Chau, Ian, et al.
Publicado: (2018)

The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma
por: Xu, Ye, et al.
Publicado: (2021)

Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
por: Huang, Jia-Xin, et al.
Publicado: (2023)

The Clinicopathological Characteristics of Alpha-Fetoprotein-Producing Adenocarcinoma of the Gastrointestinal Tract—A Single-Center Retrospective Study
por: Kong, Xiang-Xing, et al.
Publicado: (2021)

Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma
por: Zhang, Zhiguo, et al.
Publicado: (2015)

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
por: Zhao, Lei, et al.
Publicado: (2022)

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
por: Xu, Ying, et al.
Publicado: (2022)

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
por: Wang, Lijun, et al.
Publicado: (2023)

Blood Serum Alpha Fetoprotein Enhancer Binding Protein, a Tumor Suppressor, Decreases in Chronic HBV Hepatitis Patients as Hepatocellular Cancer Appears
por: Riggins, James N., et al.
Publicado: (2010)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t5pusc6b1p69vskiee177eg5fc